NCR 101
Alternative Names: Human iPSC-derived mesenchymal stromal cell therapy - Nuwacell Biotechnologies; NCR-101Latest Information Update: 04 Mar 2025
At a glance
- Originator Nuwacell Biotechnologies
- Class Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Interstitial lung diseases
Most Recent Events
- 13 Feb 2025 Phase-I/II clinical trials in Interstitial lung diseases (Parenteral) (Nuwacell Biotechnologies pipeline, February 2025)
- 13 Feb 2025 Nuwacell Biotechnologies plans a phase-I/II trial for Interstitial lung diseases in March 2025 (Parenteral) (NCT06825169)